LAS VEGAS, NV / ACCESS Newswire / October 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company pioneering the development of functional mushroom technologies, today announced the official launch of Phase II in its strategic partnership with Tryptomics, uniting Hypha's patented Mushroom Accelerator platform with Tryptomics On-Site Science Services & their contract R&D Metabolomics Pipeline to develop Hypha Labs proprietary varieties of bioreactor-optimized species and providing the gold-standard in quality assurance testing at Hypha Labs. The collaboration accelerates R&D cycles and advances the future of at-home, pharmaceutical-grade mushroom wellness.
Phase I introduced a dual-track approach to validation and scalability:
Tryptomics On-Site: Hypha Labs has accelerated its in-house analytical testing capabilities by partnering with Tryptomics to implement their in-depth analytical testing methods to optimize the accelerator's production.
Third-Party Verification Role: Tryptomics serves as an independent validation lab, confirming Hypha's internal results through Certificate of Analysis (COA) verification and reproducibility benchmarking.
Bioreactor Deployment & Duplication: Tryptomics has been equipped to deploy and operate duplicate Mushroom Accelerators in-house, mirroring Hypha Lab's systems for synchronized experimentation and protocol testing.
Genetics Collaboration: Through discussions and planning, Hypha Labs and Tryptomics is excited to announce the advancement of its mycology program through Tryptomics' next-generation sequencing analyses, TryptoMatics and marker assisted breeding, TryptoTyping.
The program also targets rapid, reproducible production of bioavailable Micro-Pearls in just eight days, providing faster iteration and scalability. With third-party COAs and internal quality control forthcoming, the first new strains are scheduled to launch in 2026 making the biochemistry of mycelium available to the wider population.
Phase II Highlights
Tryptomics On-Site provides state-of-the-art in-house production QC testing
TryptoMatics & TryptoTyping provides advanced genetics analysis and quality assurance
Third Party QC Analysis provides Hypha Labs with the ability to dig deeper
Mushroom Accelerator enables 8-day micro-ingredient production
Duplicate bioreactors deployed for synchronized R&D
First new bioreactor-optimized strains launching in 2026
"This strategic partnership aligns Hypha Labs' proprietary cultivation technology with Tryptomics' Metabolomics Pipeline to provide scalable and quality assured mushroom supplements to society," said Caleb King, Chief Science Officer and Cofounder of Tryptomics.
"Tryptomics brings the most diverse skillset under one roof and this sets us up to lead the next wave of biotech wellness," said Craig Ellins, Chief Science Officer, Hypha Labs. "Our Phase II partnership expands both speed and credibility-accelerating discovery while ensuring every result is independently validated."
Hypha Labs is currently conducting a Regulation A+ public offering, providing early investors with the opportunity to participate in the company's growth as it expands from consumer-focused devices to large-scale ingredient production.
For details on the Reg A+ campaign, visit: Invest.hyphalabs.com
About Tryptomics
Tryptomics is an early-stage biotechnology company advancing the science of natural products through cutting-edge testing services and proprietary technologies. We integrate advanced analytical chemistry with next-generation sequencing to accelerate discovery and enable Personalized Natural Medicine. Our platform delivers comprehensive chemical and genetic testing across medicinal plants, fungi, and other natural matrices, supporting the development of APIs, nutraceuticals, and novel therapeutic formulations. By combining rigorous science with scalable technology, Tryptomics empowers cultivators, researchers, and product developers to innovate with greater speed, safety, and reproducibility. Visit Us at Tryptomics.com
About Hypha Labs, Inc.
The company has developed revolutionary, cutting-edge technology focused on new methods of producing the active ingredients found in a wide array of functional mushrooms using its patent-pending mushroom accelerators. The Company is positioning itself to play an important role in the burgeoning Functional Mushroom industry in addition to being a disruptive force in future and emerging mushroom opportunities. Visit us at HyphaLabs.com.
SAFE HARBOR FORWARD LOOKING STATEMENTS:
This press release may contain forward looking statements that are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues related to our financial performance, expected revenue, contracts, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC) and on the OTC Disclosure & News Service (OTCDNS). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC and/or OTCDNS. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to the risk that we will not be able to find and secure construction contracts and the necessary assets that will enable us to become profitable. Reference is hereby made to cautionary statements set forth in the Company's most recent SEC and/or OTCDNS filings. We have incurred and will continue to incur significant expenses in our development stage, noting that there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. New lines of business in the construction industry may expose us to additional legal and regulatory costs and unknown exposure(s), the impact of which cannot be predicted at this time. Words such as "estimate," "project," "predict," "will," "would," "should," "could," "may," "might," "anticipate," "plan," "intend," "believe," "expect," "aim," "goal," "target," "objective," "likely" or similar expressions that convey the prospective nature of events or outcomes generally indicate forward-looking statements. You should not place undue reliance on these forward-looking statements, which speak only as of this press release. Unless legally required, we undertake no obligation to update, modify or withdraw any forward-looking statements, because of new information, future events or otherwise.
From time to time, the Company may post new and material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit HyphaLabs.com
For the Company's current Investor Presentation please visit www.HyphaLabs.com/deck
Investor and Media Relations:
Integrity Media Inc.
(888) 216-3595
team@integritymedia.com
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/hypha-labs-and-tryptomics-launch-phase-ii-of-strategic-partnership-pa-1080988
